Over the last decade, treatment of metastatic melanoma has profoundly improved due to the introduction of immune checkpoint inhibitors (ICI) against cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PD1). The gene discussed is CTLA4; the disease is metastatic melanoma.